Weekly Policy Update: Senate Finance Committee Advances Drug Pricing Package
By: Colorado BioScience Association Date: 07/26/2019
On Thursday, the Senate Finance Committee advanced a major legislative package that includes substantial changes to Medicare and Medicaid drug reimbursement. The bill, the Prescription Drug Pricing Re...
Learn MoreWeekly Policy Update: We Work For Health Summit—CBSA Urges Federal Lawmakers to Promote Medical Innovation and Protect Patient Access
By: Colorado BioScience Association Date: 07/22/2019
This week CBSA vice president Emily Roberts joined other state advocates in Washington, DC for the We Work For Health Summit. During the two-day event, advocates met with their respective delegation t...
Learn MoreWeekly Policy Update: Trump Administration Pulls Rebate Rule
By: Colorado BioScience Association Date: 07/15/2019
Last week the Trump Administration withdrew their proposed rebate rule that would have required manufacturer rebates to be passed through to patients in Part D and other government programs. The propo...
Learn MoreWeekly Policy Update: Drug Pricing Bills Pass Key Senate Committees
By: Colorado BioScience Association Date: 07/08/2019
Before the holiday, both the Senate Judiciary Committee and the Senate Health, Education, Labor, and Pensions (HELP) Committee advanced legislative packages aimed at lowering prescription drug prices....
Learn MoreWeekly Policy Update: New Economic Forecast Indicates Increase in Expected Revenue Above the TABOR Cap
By: Colorado BioScience Association Date: 06/20/2019
The Colorado Legislative Council released their updated budget and economic forecast this week, which showed a strong economy in the state of Colorado, an increase in expected revenue, and high wage g...
Learn MoreWeekly Policy Update: CBSA Submits Comment Letter to Senate Finance Committee’s Health Task Force Urging Repeal of the Medical Device Excise Tax
By: Colorado BioScience Association Date: 06/14/2019
Last month, leaders of the Senate Finance Committee announced the formation of several bipartisan task forces to examine 42 temporary tax provisions that expired or will expire between December 31, 20...
Learn MoreCutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals
By: Colorado BioScience Association Date: 06/13/2019
WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Phar...
Learn MoreWeekly Policy Update: CBSA Attends the 2019 BIO International Convention
By: Colorado BioScience Association Date: 06/10/2019
Last week CBSA President and CEO Jennifer Jones Paton and Vice President Emily Roberts attended the 2019 BIO International Convention in Philadelphia. The event brings together over 16,000 attendees f...
Learn MoreImproving the Reimbursement Landscape for Medical Technology Innovators
By: Colorado BioScience Association Date: 05/24/2019
CBSA continues to work with Congress and federal policymakers to improve the reimbursement landscape for medical technology innovators. Even when groundbreaking and innovative technologies meet FDA’s...
Learn MoreCMS Rolls Back Harmful Proposals in Medicare Part D
By: Colorado BioScience Association Date: 05/20/2019
Last Thursday CMS finalized a rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, which included a number of significant changes to the proposed r...
Learn More